share_log

Celularity Inc. (NASDAQ:CELUW) Short Interest Down 12.5% in January

Financial News Live ·  Feb 18, 2023 07:31

Celularity Inc. (NASDAQ:CELUW – Get Rating) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 6,300 shares, a decrease of 12.5% from the January 15th total of 7,200 shares. Based on an average daily volume of 14,600 shares, the short-interest ratio is currently 0.4 days.

Celularity Price Performance

Celularity stock remained flat at $0.10 during trading hours on Friday. Celularity has a 12-month low of $0.06 and a 12-month high of $1.99.

Get Celularity alerts:

Celularity Company Profile

(Get Rating)

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.

Further Reading

  • Get a free copy of the StockNews.com research report on Celularity (CELUW)
  • Deere Stock Raises Outlook and is Ready to Power Higher
  • DraftKings Crowning Achievement: Leverage
  • Tesla Stock Comeback Is Picking Up Steam
  • How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula
  • 3 Top-Performing Energy MLPs Deliver Price Gains, High Yield

Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment